Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

被引：0

作者：

Neil Grey ^{[1
]}

Michael Silosky ^{[2
]}

Christopher H Lieu ^{[3
]}

Bennett B Chin ^{[2
]}

机构：

[1] Radiology-Nuclear Medicine, University of Colorado School of Medicine, Anschutz Medical Campus

[2] Medical Oncology, University of Colorado School of Medicine, Anschutz Medical Campus

[3] Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus

来源：

World Journal of Gastroenterology | 2022年 / 17期

关键词：

D O I：

暂无

中图分类号：

R735 [消化系肿瘤];

学科分类号：

100214 ;

摘要：

Theranostics is the highly targeted molecular imaging and therapy of tumors.Targeted peptide receptor radionuclide therapy has taken the lead in demonstrating the safety and effectiveness of this molecular approach to treating cancers.Metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors may be most effectively imaged and treated with DOTATATE ligands. We review the current practice, safety, advantages, and limitations of DOTATATE based theranostics. Finally, we briefly describe the exciting new areas of development and future directions of gastroenteropancreatic neuroendocrine tumor theranostics.

引用

页码：1768 / 1780

页数：13

共 50 条

[1] Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
Grey, Neil
Silosky, Michael
Lieu, Christopher H.
Chin, Bennett B.
WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (17) : 1768 - 1780
[2] Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy
van Vliet, Esther I.
Teunissen, Jaap J. M.
Kam, Boen L. R.
de Jong, Marion
Krenning, Eric P.
Kwekkeboom, Dik J.
NEUROENDOCRINOLOGY, 2013, 97 (01) : 74 - 85
[3] Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Kwekkeboom, Dik J.
de Herder, Wouter W.
van Eijck, Casper H. J.
Kam, Boen L.
van Essen, Martijn
Teunissen, Jaap J. M.
Krenning, Eric P.
SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (02) : 78 - 88
[4] Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors
Gagandeep Choudhary
Samuel Galgano
Current Radiology Reports, 7
[5] Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors
Choudhary, Gagandeep
Galgano, Samuel
CURRENT RADIOLOGY REPORTS, 2019, 7 (05)
[6] The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors
Hindie, Elif
Baudin, Eric
Hicks, Rodney J.
Taieb, David
JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (04) : 522 - 524
[7] The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
Liberini, Virginia
Huellner, Martin W.
Grimaldi, Serena
Finessi, Monica
Thuillier, Philippe
Muni, Alfredo
Pellerito, Riccardo E.
Papotti, Mauro G.
Piovesan, Alessandro
Arvat, Emanuela
Deandreis, Desiree
DIAGNOSTICS, 2020, 10 (12)
[8] Utility of Midpoint Imaging in Patients Receiving Peptide Receptor Radionuclide Therapy (PRRT) for Advance Progressive Gastroenteropancreatic-Neuroendocrine Tumors (GEP-NETs)
Norman, Aurora P.
Wee, Christopher
Hobday, Timothy J.
Kendi, Ayse T.
Johnson, Geoffrey B.
Thorpe, Matthew P.
Lunn, Brendan W.
Bach, Corrie R.
Halfdanarson, Thorvardur R.
PANCREAS, 2022, 51 (03) : E45 - E45
[9] Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
Kuiper, Jelka
Zoetelief, Eline
Brabander, Tessa
de Herder, Wouter W.
Hofland, Johannes
JOURNAL OF NEUROENDOCRINOLOGY, 2025, 37 (03)
[10] Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Kwekkeboom, Dik J.
de Herder, Wouter W.
Krenning, Eric P.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2011, 40 (01) : 173 - +

← 1 2 3 4 5 →